Program Book - Confex

9:00 am
Mechanisms of Thrombosis in Antiphospholipid Syndrome: The
Role of Innate Immunity
Joyce Rauch, PhD; Research Institute of the McGill University
Health Centre; Montreal, QC, Canada
9:25 am
What is the Role of Hydroxychloroquine and Statins in the
Prevention of Thrombosis in Systemic Lupus Erythematosus
and Antiphospholipid Syndrome
Michael D. Lockshin, MD; Hospital for Special Surgery; New York,
NY
9:50 am
Novel Immunomodulatory Approaches to the Management of
Antiphospholipid Syndrome
Silvia S. Pierangeli, PhD; University of Texas Medical Branch;
Galveston, TX
Upon completion of this session, participants should be able to:
• describe how innate immune activation may contribute to
antiphospholipid syndrome, including why some individuals
with antiphospholipid develop antiphospholipid syndrome
while others do not
• define the recent data that supports a role for
immunomodulatory approaches to the management of
antiphospholipid syndrome, including some of the potential
molecular pathways/targets
• assess the evidence supporting the use of statins and/or
hydroxychloroquine for prevention of thrombosis in systemic
lupus erythematosus and antiphospholipid syndrome
W183a
Stem Cell Mediated Therapies in Autoimmune
Diseases R
Moderators: Christian Jorgensen, MD, PhD; Hospital Lapeyronie;
Montpellier, France
Jacob M. van Laar, MD, PhD; Musculoskeletal Research Group;
Newcastle, United Kingdom
9:00 am
Mesenchymal Stem Cell in the Treatment of Inflammatory
Disorders
Alan G. Tyndall, MD; University of Basel; Basel, Switzerland
ACR CLINICAL SYMPOSIA
9:00 - 10:30 am
W375d
Efficacy and Safety of Calcium and Vitamin D
Supplementation P/C PS
Moderator: Diane L. Kamen, MD, MS; Medical University of
South Carolina; Charleston, SC
9:00 am
Calcium Supplementation: Necessary for Bone, Dangerous for
the Cardiovascular System
Richard Bockman, MD, PhD; Joan and Sanford Weill Medical
College of Cornell University; New York, NY
9:25 am
Latest Understanding of Vitamin D Physiology
Robert P. Heaney, MD; Creighton University; Omaha, NE
9:50 am
Guidelines for Vitamin D Supplementation
Karen E. Hansen, MD, MS; University of Wisconsin; Madison, WI
Upon completion of this session, participants should be able to:
• describe the available data from clinical trial and cohort
studies that address the cardiovascular events reported in
calcium supplementation trials
• cite the latest understanding of the autocrine and endocrine
roles of vitamin D and what is known and unknown regarding
the roles of vitamin D in bone, cardiovascular health,
metabolism, immunology and cancer
• identify the current state of the art in establishing guidelines
for the cardiovascular system
W375c
Hereditary Angioedema C
Moderators: Tracy M. Frech, MD; University of Utah School of
Medicine; Salt Lake City, UT
Victoria K. Shanmugam, MBBS, MRCP; Georgetown University
Hospital; Washington, DC
9:00 am
Approach to Urticaria and Angioedema
Michael M. Frank, MD; Duke University; Durham, NC
WEDNESDAY
November 9, 2011
9:25 am
Different Stromal Cell Types and Immune Effects: Application to
Autoimmune Diseases
Daniele Noel; PhD; Inserm Institute, Montpellier, France
9:50 am
Organization of Immunological Memory by Bone Marrow
Stroma
Hyun-Dong Chang; PhD; Deutsches Rheuma-Forschungszentrum
Berlin ein Institut der Leibniz Gemeinschaft; Berlin, Germany
Upon completion of this session, participants should be able to:
• review the data basic biology of stem cells, on experimental
models for regenerative medicine and on different stromal cell
type (placenta, adipose, bone marrow)
• explain bone marrow niche biology
• provide an update on clinical trials in autoimmune diseases
• discuss the future strategy (allogeneic versus allogeneic cells,
number of cell, pre-activated cells) for clinical program
9:25 am
Hypereosinophilic Syndromes
Lawrence B. Schwartz, MD, PhD; Virginia Commonwealth
University; Richmond, VA
9:50 am
New Treatments for Angioedema
Bruce L. Zuraw, MD; University of California, San Diego; La Jolla,
CA
Upon completion of this session, participants should be able to:
• discuss the differential diagnosis of angioedema
• evaluate a patient with urticaria
• explain the immune mechanisms underlying the development
of hereditary angioedema
• review the currently approved therapies for the management
of patients in the acute, sub-acute and chronic phases of their
disease
118
2011 Program Book